BioVie Revenue and Competitors

BioVie Inc. (OTC PINK: BIVI) is developing novel drug therapies for life-threatening complications of chronic liver disease. Our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, NASH (non-alcoholic steatohepatitis), or alcoholism. Ascites affects about 100,000 Americans and carries an estimated 40% mortality rate within two years of being diagnosed. The Company’s new drug candidate BIV201 is about to enter a Phase 2 clinical trial in the US. It’s based on a drug (terlipressin) not yet available in the US, but approved in about 40 countries for treating related complications of liver cirrhosis. The FDA has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has Orphan drug status. BioVie has attracted funding from strategic investors including Aspire Capital, Cuong Do, the global strategy lead for Samsung, and Hari Kumar, founder of Adheron Therapeutics which he sold to Roche for $580 million. The Company has obtained FDA and Institutional Review Board (IRB) approvals to begin a Phase 2a clinical trial as early as August 2017. The trial design is based on two small overseas investigative studies which had positive results. It will be dosed in a new way as a continuous infusion using an ambulatory pump, which was invented by the Company’s Italian advisor. BioVie has secured US patent coverage for this novel dosing method for ascites and expects to be the first company to introduce terlipressin into the US market. Our goal is for BIV201 to be used by US physicians to keep these patients healthier and save billions of dollars in hospitalization costs. This could create a strong case for reimbursement coverage. Including planned follow-on indications, BioVie believes that BIV201 could potentially generate future US sales revenues exceeding $1 billion annually. For more information about BioVie and BIV201, please visit our website www.biovieinc.com.